share_log

Neuropace Shares Are Trading Lower. The Company Reported Q2 Financial Results. Wells Fargo Lowered Its Price Target on the Stock From $20 to $15.

Benzinga ·  Aug 15 03:24
Neuropace Shares Are Trading Lower. The Company Reported Q2 Financial Results. Wells Fargo Lowered Its Price Target on the Stock From $20 to $15.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment